Drug Landscape ›
Poly-L-Lactic Acid ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 25
Most-reported reactions
Swelling — 5 reports (20%) Inflammation — 4 reports (16%) Erythema — 3 reports (12%) Feeling Hot — 3 reports (12%) Dyskinesia — 2 reports (8%) Muscle Tightness — 2 reports (8%) Pain — 2 reports (8%) Pyrexia — 2 reports (8%) Chills — 1 report (4%) Dehydration — 1 report (4%)
Source database →
Poly-L-Lactic Acid in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Poly-L-Lactic Acid approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Poly-L-Lactic Acid in United States?
Bausch Health Americas, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.